HealthDay News — Uric acid (UA) therapy, in combination with thrombolysis, is more effective for decreasing stroke-related disability in women than in men, according to a study published in Stroke.
Laura Llull, MD, from University of Barcelona in Spain, and colleagues reanalyzed results from the Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke trial in which 206 women and 205 men were randomized to UA 1000 mg or placebo. The rate of excellent outcome at 90 days was assessed.
The researchers found that excellent outcome occurred in 42% of women treated with UA and 29% of those treated with placebo, versus 36 and 34%, respectively, in men. In women, UA therapy doubled the effect of placebo to attain an excellent outcome (odds ratio, 2.088; 95% confidence interval [CI], 1.050 to 4.150; P= 0.036), but not in men (odds ratio, 0.999; 95% confidence interval, 0.516 to 1.934; P= 0.997). Only in women was the interaction between treatment and serum UA levels (P< 0.001) or allantoin/UA ratio (P< 0.001) on infarct growth significant.
“In women with acute ischemic stroke treated with alteplase, the administration of UA reduced infarct growth in selected patients and was better than placebo to reach excellent outcome,” the authors write.